Cresco Labs Inc. (OTCMKTS:CRLBF – Get Free Report) was the recipient of a significant decline in short interest in July. As of July 15th, there was short interest totalling 1,744,000 shares, a decline of 12.4% from the June 30th total of 1,990,300 shares. Based on an average daily volume of 901,600 shares, the short-interest ratio is presently 1.9 days.
Wall Street Analysts Forecast Growth
CRLBF has been the topic of a number of research reports. Wedbush upped their price target on Cresco Labs from $2.50 to $3.00 and gave the stock an “outperform” rating in a research note on Thursday, May 16th. Needham & Company LLC restated a “hold” rating on shares of Cresco Labs in a research note on Thursday, May 16th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $2.63.
Get Our Latest Stock Analysis on CRLBF
Cresco Labs Stock Up 0.4 %
Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). Cresco Labs had a negative net margin of 20.32% and a negative return on equity of 6.78%. The firm had revenue of $184.30 million during the quarter, compared to analyst estimates of $183.31 million. On average, equities research analysts forecast that Cresco Labs will post -0.03 earnings per share for the current year.
About Cresco Labs
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Further Reading
- Five stocks we like better than Cresco Labs
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- P/E Ratio Calculation: How to Assess Stocks
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- CD Calculator: Certificate of Deposit Calculator
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.